Sign in
Taking people in NetherlandsPhase 2

Tests apomorphine and rifaximin in people with Parkinson's disease

Tests apomorphine, rifaximin, or both, in adults with Parkinson's disease whose levodopa breaks down early.

Key facts

Who runs it
Stichting Radboud University Medical Center
Where
Nijmegen, NetherlandsSee the site
Registry title
Management of Parkinson's disease if levodopa is broken down prematurely
Status
Recruiting
Phase
Phase 2
People taking part
81 people, planned
Started
14 May 2025
Expected to end
1 Aug 2027
Type of study
Interventional
Record updated
4 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease whose body breaks down levodopa too early. This is shown by high AADC enzyme activity or many levodopa-breaking bacteria.

Age
At least 25 years old.
Sex
Men and women can join.
Disease stage
Parkinson's disease (idiopathic parkinsonism) diagnosed by a neurologist, with documented peripheral levodopa resistance.
Earlier treatment
No antibiotics in the 12 months before and during the study, unless joining only the apomorphine part and selected by AADC activity alone. No probiotics in the past 4 weeks, with the same exception. No advanced Parkinson's therapies such as deep brain stimulation or apomorphine pens or pumps.
Biomarker or test result
Serum AADC enzyme activity of >144 mU/L, and/or faecal abundance of levodopa-metabolizing bacteria of >90,000 fragments per million.

Main reasons for not taking part

  • Atypical or genetic parkinsonism, or doubt about the Parkinson's diagnosis
  • Dementia, or current hallucinations or delusions
  • Pregnancy or breastfeeding
  • Fear of needles or injections
  • Stomach or gut disease that impairs drug absorption, such as coeliac disease

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Subject is an adult, at least 25 years of age, of either sex
  • Subject lives in the Netherlands
  • Subject can read and understand Dutch
  • Subject has completed the ethics board-approved Informed Consent
  • Subject is willing, competent, and able to comply with all aspects of the protocol, including multiple occasions of not taking their PD medication during a 12-hour period, and biospecimen collection
  • Diagnosis of Parkinson’s disease (idiopathic parkinsonism) by a neurologist, according to accepted clinical criteria
  • Documented peripheral levodopa resistance
  • Serum AADC enzyme activity of >144 mU/L (in sample taken in medicated condition) AND/OR faecal abundance of levodopa-metabolizing bacteria of >90,000 fragments per million

Who cannot take part

  • Current presence of hallucinations or delusions, or history of developing hallucinations or delusions under dopaminergic therapy. Exception: hallucinations or delusions not currently present AND currently adequately treated with a cholinesterase inhibitor to prevent recurrence
  • Any antibiotic therapy during the study period and in the 12 months preceding it, unless participant only participates in apomorphine substudy and is selected for inclusion based solely upon AADC activity, not bacterial abundance
  • Present, or in the past 14 days, use of non-selective monoamine oxidase (MAO) inhibitors (including tranylcypromine) or dual use of a selective MAO-B inhibitor (including rasagiline, safinamide) and a selective MAO-A inhibitor (including moclobemide)
  • Significant doubt over the correctness of the diagnosis idiopathic Parkinson’s disease
  • Presence of dementia
  • Presence of gastrointestinal disease associated with impaired drug absorption (e.g. coeliac disease)
  • Allergies to any of the investigational and non-investigational medications or constituents thereof
  • Present use of, or planned initiation during the study period of, advanced therapies (AT) for Parkinson’s disease including deep brain stimulation (DBS), continuous jejunal levodopa infusion (CJLI), continuous subcutaneous (fos)levodopa infusion (CSLI), apomorphine pen injections or continuous subcutaneous apomorphine infusion (CSAI)
  • Atypical or genetic parkinsonism, or parkinsonism caused by a structural laesion of the brain
  • Levodopa-resistant tremor, unless the subtotal of the ‘OFF’ MDS-UPDRS III tremor scores (item 3.15-3.18) makes up less than 15% of the ‘OFF’ MDS-UPDRS III total sum score
  • Fear of needles/injection
  • Co-morbidities that would hamper interpretation of parkinsonian disability, such as coincident musculoskeletal abnormalities
  • Not able to stand or walk without the assistance of another person (walking aids are not an exclusion criterion)
  • Pregnancy or breastfeeding
  • Documented severe and debilitating dyskinesias on levodopa, to such an extent that levodopa treatment was terminated
  • Contraindications to levodopa/benserazide
  • Present, or in the past 4 weeks, use of any probiotic preparations, unless participant only participates in apomorphine substudy and is selected for inclusion based solely upon AADC activity, not bacterial abundance

Where in Netherlands

  • Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people

About the trial

What the trial wants to find out

Can symptom management of persons with Parkinson's disease who have increased activity of the levodopa-metabolizing enzyme aromatic L-amino acid decarboxylase (AADC), or who have increased abundance of bacteria that produce the levodopa-metabolizing enzymes tyrosine decarboxylase (TDC), aromatic amino acid aminotransferase (AAT) or aromatic amino acid lactate dehydrogenase (ALDH), be improved by either circumventing the enzymatic mechanisms (using the dopamine receptor agonist apomorphine), or an antibiotic intervention against enzyme-producing bacteria (rifaximin), or both?

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Management of peripheral levodopa resistance in Parkinson’s disease
Plain-language title
Tests apomorphine and rifaximin in people with Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 February 2026